Fundraising Fox
🦊/Companies
Sign in

Eikonizo Therapeutics

Beverly, US · Founded 2017 · Delaware corporation · 13 employees on LinkedIn · 1 known investors

Find your way into Eikonizo Therapeutics

475 people in our graph share verified history with the Eikonizo Therapeutics team — schools, employers, funds. One of them is your warm intro.

Adam Valkinunlockedknows Janice Kranz, PhD · together at Harvard University (overlapped)
×6knows the team · via Harvard University
×5knows the team · via The Broad Institute of MIT and Harvard

Eikonizo develops small molecule therapeutics targeting neurodegenerative and cardiorenal diseases. The company is focused on creating novel, disease-modifying treatments to improve patient outcomes.

AI & Machine LearningBiotechDeep TechHealthtechMedical Devices

Founders & leadership

Eikonizo Therapeutics was founded in 2017 by Janice Kranz, PhD.

JKJanice Kranz, PhD
Janice Kranz, PhDinCo-FounderJanice Kranz holds a PhD in biology from Harvard and brings 25 years of experience in startup biotech and nonprofit roles, with expertise in drug discovery research, business development, and securing research funding.
WS
William ShawNamed on SEC filing
SW
Stacie WeningerNamed on SEC filing
JK
Janice KranzNamed on SEC filing

Board

KKKevin Kinsella
Kevin KinsellaBoard director

Investors · 1

Mission BiocapitalSan Francisco · $500K

Reported raises · per SEC filings

Form D private placements

$2.4M disclosed across 2 rounds · 2018

▶$371.4KraisedMay 2018 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Janice KranzExecutive Officer, Director
  • Stacie WeningerDirector
  • William ShawExecutive Officer, Director
  • Kevin KinsellaDirector
Offering amount
$841.1K
Amount sold
$371.4K
First sale
May 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedApr 2018 · 2 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • William ShawExecutive Officer, Director
  • Kevin KinsellaDirector
  • Stacie WeningerDirector
  • Janice KranzExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
First sale
Mar 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Actio Biosciences, Inc.3 shared keywordsActio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions. It focuses on identifying dysregulated gene activity and designing therapies to restore balance and address the root causes of disease.

Companies competing with Eikonizo Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Eikonizo Therapeutics Receives Equity Investment From Novo Nordiskfinsmes.com · Dec 2024Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Developmentfinance.yahoo.com · Dec 2024Eikonizo Therapeutics, Inc. announced that it has received funding from Novo Nordisk A/S | MarketScreenermarketscreener.com · Dec 2024

Frequently asked questions

What does Eikonizo Therapeutics do?
Eikonizo develops small molecule therapeutics targeting neurodegenerative and cardiorenal diseases. The company is focused on creating novel, disease-modifying treatments to improve patient outcomes.
Who founded Eikonizo Therapeutics?
Eikonizo Therapeutics was founded by Janice Kranz, PhD in 2017.
Who are Eikonizo Therapeutics's investors?
Eikonizo Therapeutics's investors include Mission Biocapital.
How much funding has Eikonizo Therapeutics raised?
Eikonizo Therapeutics has disclosed $2.4M raised across 2 rounds.
Where is Eikonizo Therapeutics headquartered?
Eikonizo Therapeutics is headquartered in Beverly, US.